ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 0191 • ACR Convergence 2022

    Patient-reported Outcomes to Assess Dyspnea in Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Hypertension, a Systematic Literature Review of Measurement Properties

    Jacqueline Lemmers1, Madelon Vonk2 and Els Ende, van den3, 1Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, 2Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 3Radboudumc, Nijmegen, Netherlands

    Background/Purpose: This COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN)-based systematic review aims to identify and summarize the quality of measurement properties of…
  • Abstract Number: 0421 • ACR Convergence 2022

    Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Prior bDMARD Treatment: Analysis of a Phase 3 Trial

    Atul Deodhar1, Helena Marzo-Ortega2, Joseph Wu3, Cunshan Wang3, Oluwaseyi Dina4, Keith S Kanik3, Lara Fallon5 and Lianne Gensler6, 1Oregon Health & Science University, Portland, OR, USA, Portland, OR, 2Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, 3Pfizer Inc, Groton, CT, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Montréal, QC, Canada, 6Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Prior exposure to biologic (b)DMARD therapy of patients (pts) with AS may influence treatment response.1-3 Tofacitinib is an oral JAK inhibitor for the treatment…
  • Abstract Number: 0903 • ACR Convergence 2022

    Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis

    Emil Rydell1, Lennart Jacobsson2 and Carl Turesson3, 1Lund University, Malmö, Sweden, 2Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD). Systemic inflammation, driven by cytokines such as TNF, IL-6 and IL-17A,…
  • Abstract Number: 1262 • ACR Convergence 2022

    Clinical and Ultrasound-based Composite Disease Activity Indices and Radiographic Progression in Rheumatoid Arthritis

    Irina Gessl1, Thomas Deimel1, Paul Studenic1, Giorgio Tamborrini2, Pascal Zufferey3, Daniel Aletaha4, Burkhard Moeller5 and Peter Mandl1, 1Medical University of Vienna, Vienna, Austria, 2Ultrasound Center and Institute for Rheumatology, Zürich, Switzerland, 3HFR, Fribourg, Switzerland, 4Medical University Vienna, Wien, Austria, 5Inselspital - University Hospital Bern, Bern, Switzerland

    Background/Purpose: Musculoskeletal ultrasound (US) has been reported to predict radiographic progression in rheumatoid arthritis (RA). The aim of the study was to test the predictive…
  • Abstract Number: 1540 • ACR Convergence 2022

    Correlations of Soluble Interleukin-2 Receptor Serum Levels with Markers of Inflammation and Pathological High-sensitivity Troponin T and Its Possible Role as a Predictor of Early Clinical Progress in Systemic Sclerosis

    Luise Schumacher1, Sebastian Klapa2, Antje Mueller3 and Gabriela Riemekasten4, 1University of Lübeck, Lübeck, Germany, 2Universityhospital Schleswig-Holstein; University of Lübeck; Clinic of Rheumatology and Clinical Immunology, Luebeck, Germany, 3University Hospital Schleswig-Holstein (UKSH), Lübeck, 4University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany

    Background/Purpose: Systemic sclerosis (SSc) is characterized by chronic inflammation leading to damage of the vascular endothelium and excessive collagen deposition in several target organs. The…
  • Abstract Number: 1974 • ACR Convergence 2022

    Which ACR Response Definition Should Be Used for Disease Activity Claims in Approval Studies of Rheumatoid Arthritis? A Systematic Evaluation

    Andreas Kerschbaumer1, Victoria Konzett2, Josef Smolen1 and Daniel Aletaha3, 1Medical University of Vienna, Vienna, Austria, 2Division of Rheumatology / Department of Medicine III / Medical University of Vienna, Vienna, Austria, 3Medical University Vienna, Wien, Austria

    Background/Purpose: The American College of Rheumatology (ACR) response definition was developed in 1995 by Felson et al. as a composite outcome and has been the…
  • Abstract Number: 2142 • ACR Convergence 2022

    Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial

    William Tillett1, Laura Coates2, Mohamed Sharaf3, Marlies Neuhold4, Elke Theander5, Paul Bergmans6, May Shawi7, Michelle Perate8, Christine Contré9 and Philip Helliwell10, 1Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 4Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, 5Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, 6Formerly at Janssen, Breda, Netherlands, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Janssen Scientific Affairs, LLC, Horsham, PA, 9Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, 10Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Accurate assessment of psoriatic arthritis (PsA) disease activity in clinical practice requires a feasible, continuous, multidimensional composite instrument to assess key domains of this…
  • Abstract Number: 0192 • ACR Convergence 2022

    Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis

    Laura Coates1, Arthur Kavanaugh2, Erin McDearmon-Blondell3, Arthur Mandelin4, Tianming Gao5 and William Tillett6, 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 2University of California San Diego, La Jolla, CA, 3AbbVie, Inc., Mettawa, IL, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5AbbVie, Inc., North Chicago, IL, 6Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

    Background/Purpose: RAPID3 (Routine Assessment of Patient Index Data 3) is a dis­ease activity index calculated from 3 patient-reported measures: phys­ical function, pain, and patient global…
  • Abstract Number: 0423 • ACR Convergence 2022

    Direct and Indirect Effect of TNFi on BASMI Components in People with Axial Spondyloarthritis: A Longitudinal Study

    Ana Pinto1, Claire Harris2, Rhys Hayward2, Andrew Keat2 and Pedro Machado2, 1Local Health Unit of Guarda, Barcelos, Portugal, 2Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom

    Background/Purpose: The Bath Ankylosing Spondylitis Metrology Index (BASMI) is an index of spinal mobility for people with axial spondyloarthritis (axSpA). BASMI is one of the…
  • Abstract Number: 0940 • ACR Convergence 2022

    Effect of an 8-week Tailored Physical Therapy Program on Sexual Function in Women with Systemic Sclerosis and Idiopathic Inflammatory Myopathies: A Pilot Controlled Study

    Barbora Hermankova1, Maja Spiritovic1, Sabina Oreska2, Hana Storkanova2, Karel Pavelka3, Ladislav Šenolt4, Jiří Vencovský4, Radim Becvar2 and Michal Tomcik2, 1Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, 4Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Systemic rheumatic diseases like systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM) may affect all aspects of life, including sexual health. However, no non-pharmacological…
  • Abstract Number: 1268 • ACR Convergence 2022

    Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program

    William Tillett1, Laura Coates2, Mitsumasa Kishimoto3, Arathi Setty4, Tianming Gao5, Ralph Lippe6 and Philip Helliwell7, 1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Kyorin University School of Medicine, Yokohama, Japan, 4AbbVie, Inc., Staten Island, NY, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Inc, Wiesbaden, Germany, 7Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Composite measures using 3-visual analog scale (VAS; physician's global assessment, patient's global assessment, and skin) or 4-VAS (physician's global assessment, joints, skin, and pain)…
  • Abstract Number: 1595 • ACR Convergence 2022

    Association of Sustained Lupus Low Disease Activity State with Improved Outcomes in SLE: A Multinational Prospective Cohort Study

    Vera Golder1, Rangi Kandane-Rathnayake1, Ning Li1, Worawit Louthrenoo2, Yi-Hsing Chen3, Jiacai Cho4, Aisha Lateef5, Laniyati Hamijoyo6, Luo Shue Fen7, Yeong-Jian Wu7, Sandra Navarra8, Leonid Zamora8, Zhanguo Li9, An Yuan10, Sargunan Sockalingam11, Yasuhiro Katsumata12, Masayoshi Harigai12, Yanjie Hao13, Zhouli Zhang14, Duminda Basnayake15, Madelynn Chan16, Jun Kikuchi17, Tsutomu Takeuchi18, Sang-Cheol Bae19, Fiona Goldblatt20, Shereen Oon21, Sean O'Neill22, Kathryn Gibson22, Kristine Ng23, Hui Nee Annie Law24, Nicole Tugnet25, Sunil Kumar26, Cherica Tee27, Michael Tee27, Yoshiya Tanaka28, Chak Sing29, Alberta Hoi30, Mandana Nikpour31 and Eric Morand32, 1Monash University, Clayton, Australia, 2Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, 3Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, 4National University Health System (NUHS), Singapore, Singapore, 5National University Hospital, Singapore, Singapore, 6Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, 7Chang Gung Memorial Hospital, Taoyuan, Taiwan, 8University of Santo Tomas, Manila, Philippines, 9Peking University People's Hospital, Beijing, China, 10Peking University Health Science Center, Beijing, China, 11University of Malaya, Kuala Lumpur, Kuala Lumpur, Malaysia, 12Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 13The University of Melbourne, Melbourne, Australia, 14Peking University First Hospital, Beijing, China, 15Teaching Hospital Kandy, Kandy, Sri Lanka, 16Tan Tock Seng Hospital, Singapore, Singapore, 17Keio University School of Medicine, Tokyo, Japan, 18Keio University and Saitama Medical University, Tokyo, Japan, 19Hanyang University Medical Center, Seoul, Republic of Korea, 20Flinders Medical Centre, Adelaide, Australia, 21St Vincent's Hospital, Fitzroy, Australia, 22Liverpool Hospital, Sydney, Australia, 23North Shore Hospital, Auckland, New Zealand, 24Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, 25Greenlane Clinical Centre, Auckland, New Zealand, 26Middlemore Hospital, Auckland, New Zealand, 27University of the Philippines, Quezon City, Philippines, 28University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 29The University of Hong Kong, Pok Fu Lam, Hong Kong, 30Monash Health, Melbourne, Australia, 31The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, 32Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia

    Background/Purpose: Since the initial prospective validation of the Lupus Low Disease Activity State (LLDAS), this treat-to-target endpoint has been studied in numerous other cohorts, with…
  • Abstract Number: 1990 • ACR Convergence 2022

    Artificial Intelligence Applied to Transcriptomics Profiling of Synovial Tissue Biopsies Accurately Predicts Rheumatoid Arthritis Patients Who Will Respond or Be Refractory to Standard Biological Treatments

    Giorgio CASABURI, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA

    Background/Purpose: In recent years, biological therapies have revolutionized treatments of Rheumatoid Arthritis (RA). However, about 40% of RA patients do not respond to given biologics…
  • Abstract Number: 2170 • ACR Convergence 2022

    Validation of Ranked Composite Important Difference (RCID) Score in Early Diffuse Cutaneous Systemic Sclerosis

    Francesco Del Galdo1, Suiyuan Huang2, Lesley-Anne Bissell3, sindhu johnson4, Daniel Furst5 and Dinesh Khanna6, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, 2University of Michigan, Ann Arbor, MI, 3University of Leeds, Leeds, United Kingdom, 4Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, 5University of California Los Angeles, Los Angeles, CA, 6Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: The Ranked Composite Important Difference (RCID) in diffuse cutaneous Systemic Sclerosis ( dcSSc) is a clinically and patient meaningful composite score for outcome of…
  • Abstract Number: 0256 • ACR Convergence 2021

    Consensus Approach to a Treat to Target Strategy in Juvenile Idiopathic Arthritis Care: Report from the 2020 Pediatric Rheumatology Care and Outcomes Improvement Network Consensus Conference

    Tala El Tal1, Meghan Ryan2, Brian Feldman3, Catherine Bingham4, Jon Burnham5, Michelle Batthish6, Danielle Bullock7, Kerry Ferraro8, Mileka Gilbert9, Beth Gottlieb10, Julia Harris11, Melissa Hazen12, Ronald Laxer13, Tzielan Lee14, Daniel Lovell15, Melissa Mannion16, Laura Noonan17, Edward Oberle18, Anne Paul19, Janalee Taylor20, Jennifer Weiss21, Cagri Yildirim-Toruner22 and Esi Morgan23, 1University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, 2University of Minnesota, Vadnais Heights, MN, 3The Hospital for Sick Children, Toronto, ON, Canada, 4Penn State Children's Hospital, Allentown, PA, 5Children's Hospital of Philadelphia, Philadelphia, PA, 6McMaster University, Hamilton, ON, Canada, 7University of Minnesota, Minneapolis, MN, 8Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, 9Medical University of South Carolina, Charleston, SC, 10Cohen Children's Medical Center, Lake Success, NY, 11Children's Mercy Kansas City, Overland Park, KS, 12Boston Children's Hospital, Boston, MA, 13SickKids, Toronto, ON, Canada, 14Stanford University School of Medicine, Palo Alto, CA, 15Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, 16University of Alabama at Birmingham, Birmingham, AL, 17Levine Children's Hospital/Carolinas Healthcare System, Charlotte, NC, 18Nationwide Children's Hospital, Columbus, OH, 19Cincinnati Children's Hospital Medical Centre, Cincinnati, OH, 20Cincinnati Children's Hospital, Cincinnati, OH, 21Hackensack University Medical Center, Hackensack, NJ, 22Texas Children's Hospital/Baylor College of Medicine, Houston, TX, 23Seattle Children's Hospital, Seattle, WA

    Background/Purpose: Treat to target (T2T) is a strategy of adjusting treatment until a therapeutic target is reached. There is growing evidence supporting the use and…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology